NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Zevra Therapeutics Shares Plunge After EU Rejects Arimoclomol for Rare Disease

Company plans to request re-examination.

Zevra Therapeutics Shares Plunge After EU Rejects Arimoclomol for Rare Disease
Credit: Zevra Therapeutics
Already have an account? Sign in.
Featured/ 07/24/2026 · 8:53 AM
ZVRA
/ Don’t stop at just one post.

Related↓

BTIG Initiates Buy on Zevra After $50M Portfolio Sale and Debt-Free Move
03/16/2026 · 8:29 AM

BTIG Initiates Buy on Zevra After $50M Portfolio Sale and Debt-Free Move

BTIG starts coverage on ZVRA with Buy rating and $23 target after Zevra sells SDX portfolio for $50 million and becomes debt-free.

/ Subscriber only
/ Read more

Feed↓

FDA Approves First SMA Drug That Targets Muscle Loss, Not Just Nerves
Featured/ 09/11/2026 · 5:55 PM

FDA Approves First SMA Drug That Targets Muscle Loss, Not Just Nerves

The FDA approved Scholar Rock’s Isembyld, the first SMA therapy aimed at muscle wasting in patients already on nerve-targeted treatment.

/ Subscriber only
AstraZeneca’s Etcamah Combination Falls Short of Statistical Significance in SERENA-4
Featured/ 09/11/2026 · 4:48 PM

AstraZeneca’s Etcamah Combination Falls Short of Statistical Significance in SERENA-4

The Phase III SERENA-4 trial did not meet its primary PFS endpoint in untreated advanced ER-positive, HER2-negative breast cancer, despite a numerical benefit.

/ Subscriber only
Citi Says AppLovin Is Positioned to Meet or Beat Q3 Guidance
09/11/2026 · 4:30 PM

Citi Says AppLovin Is Positioned to Meet or Beat Q3 Guidance

Citi added a 90-day upside view on AppLovin with a $600 target, calling Q3 concerns misguided.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2025
Email address Subscribe